BIOG vs. OCI, ICGT, APAX, RICA, SDP, JEO, MUT, APEO, TFIF, and SAIN
Should you be buying The Biotech Growth Trust stock or one of its competitors? The main competitors of The Biotech Growth Trust include Oakley Capital Investments (OCI), ICG Enterprise Trust (ICGT), Apax Global Alpha (APAX), Ruffer Investment (RICA), Schroder Investment Trust - Schroder AsiaPacific Fund (SDP), European Opportunities Trust (JEO), Murray Income Trust (MUT), abrdn Private Equity Opportunities (APEO), TwentyFour Income (TFIF), and Scottish American Investment (SAIN). These companies are all part of the "asset management" industry.
The Biotech Growth Trust vs. Its Competitors
The Biotech Growth Trust (LON:BIOG) and Oakley Capital Investments (LON:OCI) are both small-cap asset management industry companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk.
In the previous week, The Biotech Growth Trust's average media sentiment score of 0.00 equaled Oakley Capital Investments'average media sentiment score.
10.5% of The Biotech Growth Trust shares are owned by institutional investors. Comparatively, 25.6% of Oakley Capital Investments shares are owned by institutional investors. 1.5% of The Biotech Growth Trust shares are owned by company insiders. Comparatively, 12.5% of Oakley Capital Investments shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
The Biotech Growth Trust has a beta of 0.5, indicating that its stock price is 50% less volatile than the S&P 500. Comparatively, Oakley Capital Investments has a beta of 0.69, indicating that its stock price is 31% less volatile than the S&P 500.
Oakley Capital Investments has higher revenue and earnings than The Biotech Growth Trust. The Biotech Growth Trust is trading at a lower price-to-earnings ratio than Oakley Capital Investments, indicating that it is currently the more affordable of the two stocks.
The Biotech Growth Trust has a net margin of 95.33% compared to Oakley Capital Investments' net margin of 88.84%. The Biotech Growth Trust's return on equity of 26.96% beat Oakley Capital Investments' return on equity.
Summary
Oakley Capital Investments beats The Biotech Growth Trust on 8 of the 11 factors compared between the two stocks.
Get The Biotech Growth Trust News Delivered to You Automatically
Sign up to receive the latest news and ratings for BIOG and its competitors with MarketBeat's FREE daily newsletter.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
The Biotech Growth Trust Competitors List
Related Companies and Tools
This page (LON:BIOG) was last updated on 10/14/2025 by MarketBeat.com Staff
